Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
NCT03406780 is registered in ClinicalTrials.gov with Capricor Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
- Lead sponsor
- Capricor Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 4, 2018
- Completion date
- March 10, 2020
- Enrollment
- 20 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.